Finanzen von BioAge Labs, Inc. (BIOA)BIOABioAge Labs, Inc.

Evaluating the bottom line, BioAge Labs, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1196.78%, while the net margin is -1064.75%. These profitability ratios, combined with a Return on Equity (ROE) of -28.21%, provide a clear picture of how effectively BIOA converts its operational activities into shareholder value.

In the context of the broader market, BIOA competes directly with industry leaders such as LYEL and RCKT. With a market capitalization of $273.10M, it holds a significant position in the sector. When comparing efficiency, BIOA's gross margin of 100.00% stands against LYEL's 100.00% and RCKT's N/A. Such benchmarking helps identify whether BioAge Labs, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a Q2 revenue of $2.45 million, a 1.7% increase year-over-year, but also a wider net loss of $26.09 million, indicating ongoing financial challenges despite revenue growth.